APROBATION OF PLATELET AGGREGATION INHIBITOR FROM ECHIS MULTISQUAMATIS SNAKE VENOM IN VITRO, IN VIVO and EX VIVO Zhelavskyi M.A., Platonov M. O., Kucheryavyi Y. Р., Stohnii Y. M.

Details: Hits: 225

ISSN 2410-7751 (Print)
ISSN 2410-776X (Online)

cover biotech acta general

Biotechnologia Acta Т. 16, No. 5 , 2023
P. , Bibliography 17, Engl.
UDC::57.088.2
https://doi.org/10.15407/biotech

APROBATION OF PLATELET AGGREGATION INHIBITOR FROM ECHIS MULTISQUAMATIS SNAKE VENOM IN VITRO, IN VIVO and EX VIVO

Zhelavskyi M.A.^{1, 2}, Platonov M.O.¹, Kucheryavyi Y.Р.¹, Stohnii Y.M.¹

¹ Palladin Institute of biochemistry NAS of Ukraine,
^2.ZL “Success Academy”, Kyiv region.

Snake venom-derived platelet aggregation inhibitors can be promising antiplatelet medications that can allow to avoid the risk of bleeding and treatment resistance, particularly in aspirin-resistant patients.

Aim. The purpose of our study was to assess the effectiveness of a platelet aggregation inhibitor derived from Echis multisquamatis snake venom in various settings, including in vitro, in vivo, and ex vivo.

Methods. We examined a polypeptide from Echis multisquamatis venom, purified using a recently developed chromatography protocol, across multiple models. This polypeptide was introduced into platelet-rich blood plasma and administered intravenously to rats. The effects on platelet aggregation were assessed using aggregometry, focusing on ADP-induced aggregation.

Results. Our findings revealed that a concentration of 0.040 mg/ml significantly reduced platelet aggregation in vitro. Remarkably, this dosage also proved effective when administered intravenously in laboratory animals, reaffirming its potential as a robust antiplatelet agent. In the final phase of our study, the polypeptide demonstrated its ability to inhibit platelet aggregation in blood plasma of pregnant woman with aspirin resistance, presenting a promising avenue for innovative treatment approaches in such cases.

Conclusions. This study underscores the potential of the Echis multisquamatis venom-derived polypeptide as a promising antiplatelet agent, effective in diverse scenarios, including aspirin resistance. Further research and clinical trials are imperative to fully harness its therapeutic potential.

Key words: disintegrin, blood plasma, platelets, thrombosis, blood coagulation, platelet aggregation, animal model.